CAII/VII-IN-1

CAII/VII-IN-1 is an orally active hCA II (KI = 12.3 nM), and hCA VII (KI = 22.6 nM) inhibitor, showing no significant activity against hCA I. CAII/VII-IN-1 shows excellent neuroprotective activity in vivo Pilocarpine (HY-B0726A) -induced seizure model. CAII/VII-IN-1 can upregulate KCC2 and inhibit mTOR, exerting neuroprotective effects. CAII/VII-IN-1 does not show any significant neurotoxic effects or alterations in liver and kidney function. CAII/VII-IN-1 can be used for the study of epilepsy[1].

Product Specifications

CAS Number

[3085155-69-4]

UNSPSC

12352005

Target

Carbonic Anhydrase; mTOR; NKCC

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

ClC1=CC=C(C=C1)C2=NN(C=C2/C=N/NC(C3=C(N(N=N3)C4=CC=C(C=C4)S(N)(=O)=O)C)=O)C5=CC=C(C=C5)S(C)(=O)=O

Molecular Formula

C27H23ClN8O5S2

Molecular Weight

639.11

References & Citations

[1]ie Y, et al. Development of potent glutathione transferase Omega-1 inhibitors with applications in inflammation and cancer therapy. Eur J Med Chem. 2025 Dec 5;299:118072.